Chris Gibson built the pioneering AI biotech Recursion Pharmaceuticals on a foundation of bold promises. But after more than ...
1d
Recursion outlines runway into early 2028 while maintaining 2026 cash operating expenses under $390M
Financial framing remained anchored on the same runway and 2026 cash operating expense guidance, while Q1 2026 highlighted a "30% year-over-year reduction" in cash operating expenses and quarter-end ...
New research exposes how prompt injection in AI agent frameworks can lead to remote code execution. Learn how these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results